Investment Q&A

Q: Can you please update your analysis of BMI. Can they overcome the loss of their patents on key drugs?

Q: Can you comment on their earnings release and how do you see their prospects? Would you consider it a buy/sell/hold? Thanks

Q: This is a company that you recommended back in 2024 and it has seen a sharp decline in their share price over the past 18 months. Do you see the current price as an entry point for a new position? In general, is this a stock you'd recommend or avoid?

Q: Your thoughts on yesterday's earnings? Would you be comfortable adding? Is this a sell, buy, or hold?
Thank you
P

Q: Cold is having a good day today. whats going on with this stock? when is it ex div.
Thanks

Q: Received my first dividend on this US listed stock in my US Rif. After looking at all the dividends in and deductions out, I calculate I'm paying approx. 47% with holding tax! 37% appears to be on the US side, 10% on the Canadian side. Sound about right to you? If so I'll be selling this right quick!
Also, do I now have to worry about filing US taxes?

Q: From Michael Burry.

Palantir’s accounts receivable (AR) is first up. The traditional metric for AR is Days Sales Outstanding (DSO), with higher DSO implying customers are taking their time to pay for Palantir’s services for one reason or another.

In 9 of the last 12 quarters, AR grew faster than revenue – a persistent pattern generally attached to nefarious tricks such as channel stuffing, aggressive revenue recognition, or extended payment terms used as sales concessions. For real subscription businesses, AR growth should track revenue growth closely. When AR is volatile or outgrows revenue, it means the company is booking sales faster than it is collecting cash.

Reason to sell or not, how big a deal is it?

Thank you.

Q: I must be missing something re MU. It is trading aa bit over 10x next years earnings, unless my sources are wrong. My question is why? They are building two new huge production facitilites in Boise, one in Japan and one in New York, because the supply can't keep up with demand. Their margins have increased from around 15% 18 months ago to 55% now, and they are projecting 66% in Q1.

I know they have two major (successful) competitors, but the demand is so strong, and the backlogs so long, I just don't see any major risk for at least the next 12-18 months. Am I wrong? So why is the PE so low?

Q: Hello,
Could you comment on most recent Roku earnings?
Many thanks

Stephane

Q: Hello team,

ALGN (up 46% in the past 3 months): Buy, hold, or sell? Why?

TWST (up 116% in the past 3 months): Buy, hold, or sell? Why?


Long holder of both and still deeply under water. So, I am wondering what is behind new signs of life!

As always, I appreciate your unemotional insight and guidance for us all!

Q: Hi 5i,

Would appreciate your thoughts on AMD moving forward.

I have held the stock for over 3 years and have done well but considering selling for other opportunities in the market at the moment.

Do you believe AMD has the potential to eventually catch up to Nvidia over the next few years? Can it keep capturing market share from intel?

Thank you,

Greg C.

Q: Good morning, Peter and Team,

Paul Krugman recently wrote the following in a Substack post:

'And the damage from the assault on vaccines continues to widen. Last week the Food and Drug Administration refused to review Moderna’s new mRNA-based flu vaccine. They didn’t reject it based on evidence; they wouldn’t even look at it, in line with RFK Jr.’s evidence-free, dogmatic assertion that mRNA technology, which gave us Covid vaccines, is useless and harmful. Pharmaceutical companies, understandably, are retreating from vaccine development.'

Is this another reason to avoid, or to at least reduce exposure to companies involved in vaccine development? For those of us with ETFs in the Health Care Sector, this becomes a daunting task.

Personally, I can't wait until the US midterms so that hopefully there can be some hope that this madness will end.

As always, thanks for your insights.

Q: Hello, can you comment on Palo Alto’s latest earnings report and guidance? Is the price drop (Wed morning) overdone? Thanks

Q: Hello Peter and 5i Team,

Can you please comment on GRMN earnings ? Is there anything else attributing to the share price spike today that you can see?

Thanks,
Dave

Q: Hello Team and good Family Day for the ones in Ontario,

Apart from the market fixation now on overspending on AI which costs a bundle and may not generate more profit, I read somewhere an analyst making a parallel between GE (pre-separation in 3 separate entities) and the 3 members of the Mag 7 listed above. He says they may be going the way GE did when the market started pricing conglomerates the way it did for the last 15 years which consequently brought GE to a very low multiple. What did it for GE, he says, was being involved in different and unrelated businesses, for one, and one strong entity pulling the weight of costly money losing members for another. He says it is also true especially in the AMZN and GOOG cases. What do you think? As always thanks for your strong insight, Adel.

Q: Hello Team 5i & Everyone,

May I have your updated assessment on the quality of Devon Energy Corporation (DVN:US) please?

Thank you,

Sandra

Q: Their latest acquisition seemed to be a good move into the drone data recovery space and with their latest earnings growth and strong business model (eg. getting paid their subscriptions for the gov't upfront to provide upfront cash) and growing focus on non-government areas (eg. military or private sector w/ the Corellium acquisition) what am I missing with this company? Why are investors staying away and creating such volatility when results are good.

Headscratcher on this one...

Q: Could i have your thoughts on this cloud provider- chart looks good - i understand sales are ramping in their AI division

Q: I just sold a position in Regeneron, and I am looking to replace it with another name in the healthcare space. I already hold ISRG, but I am reticent to add to it while it seems to trade sideways. Lilly has performed well, but I am unsure if it is now fully valued.A recent interviewee on CNBC had mentioned Amgen and Gilead as names which could do well. Any suggestions for names to consider in the healthcare space? I’d be okay with both Canadian and US names. Thanks so much, and I look forward to your response.

Q: Please rank these consumer stocks for a new buy and suggest any you may prefer. Thank you.